Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences is positioned for durable growth because 3Q26 delivered a broad-based beat, with total revenue of $1.12 billion, up 41% year over year, while non-GAAP diluted EPS reached about $3.3 and management raised FY26 Ingrezza guidance to $2.9 billion–$2.925 billion. Its core driver remains Ingrezza, where ~$801 million in sales reflected strong volume and record prescriptions, and the company expects double-digit volume growth in 2027 to more than offset mid-to-high-single-digit pricing pressure with access at least matching 2026. Crenessity and VYKAT XR add diversification, as Crenessity annualized above $800 million with only about 15% penetration of diagnosed classic CAH and VYKAT XR exceeded consensus despite a temporarily delayed growth trajectory, while multiple 2027 pipeline readouts provide further upside catalysts.

Neurocrine Biosciences is vulnerable to slower-than-expected growth from Ingrezza and Crenessity, which would pressure revenue expansion and weaken the company’s ability to sustain its current commercial momentum. Its valuation thesis also depends heavily on pipeline success, so any clinical failures, side effects, or regulatory setbacks could reduce future approval opportunities and constrain long-term earnings potential. Additional competition could further erode market share and pricing power, and in a downside scenario this combination would imply a DCF-based valuation of $85.